tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Hypopigmentation D017496 2 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Vitiligo D014820 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Myxedema D009230 2 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Paresis D010291 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Angiofibroma D018322 2 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Mediastinitis D008480 2 associated lipids
Oliguria D009846 2 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Fibroadenoma D018226 2 associated lipids
Mucinoses D017520 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Labyrinthitis D007762 2 associated lipids
Paraproteinemias D010265 2 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Fungemia D016469 2 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Pharyngitis D010612 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Leg Injuries D007869 2 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Histiocytosis D015614 2 associated lipids
Seminoma D018239 2 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Rupture D012421 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Cheilitis D002613 2 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Earache D004433 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Tongue Diseases D014060 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Nail Diseases D009260 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Takahashi K et al. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24655975
Tanabe M et al. The influence of donor and recipient strains in isolated small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7527986
Tabasco-Minguillan J et al. Long-term insulin requirement after liver transplantation with FK 506 in American veterans. 1993 Transplant. Proc. pmid:7679839
Klintmalm GB et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679840
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Ericzon BG et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. 1991 Transplant. Proc. pmid:1721273
Tanaka M et al. Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation: inhibition of humoral response and acceptance of donor organs. 1996 Transplant. Proc. pmid:8623341
Platz KP et al. FK506 for primary and rescue therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636570
Ye Q et al. Functional analysis of hamster kidney xenografts in the rat: possible functional incompatibility and adaptation of hamster kidney grafts in a xenogenic rat environment. 1996 Transplant. Proc. pmid:8623350
Taibi A et al. Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. 1998 Transplant. Proc. pmid:9636571
Shimada H et al. Existence of serum p53 antibodies in cyclosporine A-treated transplant patients: possible detection of p53 protein over-expression. 2000 Transplant. Proc. pmid:11119931
Vela CG et al. Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients. 2000 Transplant. Proc. pmid:10715453
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Rodrigo E et al. High initial blood levels of tacrolimus in overweight renal transplant recipients. 2005 Transplant. Proc. pmid:15866635
Martínez-Castelao A et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. 2005 Transplant. Proc. pmid:16386539
Sessa A et al. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients. 2009 Transplant. Proc. pmid:19460510
Spagnoletti G et al. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. 2009 Transplant. Proc. pmid:19460509
Armenta Bautista A et al. Renal Transplantation in Second-Level Private Hospitals in the State of Mexico. 2018 Transplant. Proc. pmid:29579825
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Stratta RJ Late acute rejection episodes after vascularized pancreas transplantation. 1998 Transplant. Proc. pmid:9636633
Goulet O et al. Small bowel transplantation alone or with the liver in children: changes by using FK506. 1998 Transplant. Proc. pmid:9636636
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Hampel G et al. Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors. 1999 Transplant. Proc. pmid:10578279
Ishibashi M et al. Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period. 1999 Transplant. Proc. pmid:10578281
Yang S et al. Characteristics of long-term immunosuppressive therapy in Chinese pediatric renal transplant patients: a single-center experience. 2009 Transplant. Proc. pmid:20005361
Hohage H et al. Cyclosporine and tacrolimus: influence on cardiovascular risk factors. 2005 Transplant. Proc. pmid:15848615
Seymen P et al. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters. 2009 Transplant. Proc. pmid:20005364
Schuller S et al. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. 2005 Transplant. Proc. pmid:15848653
Nassar CA et al. Effects of long-term FK 506 therapy on the alveolar bone and cementum of rats. 2009 Transplant. Proc. pmid:19545747
Karabulut AB and Ara C Melatonin ameliorates tacrolimus (FK-506)'s induced immunosupressive effect in rat liver. 2009 Transplant. Proc. pmid:19545748
Demirbas A et al. FK 506 in simultaneous pancreas/kidney transplantation: the University of Miami experience. 1997 Transplant. Proc. pmid:9365608
Kliem V et al. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. 1997 Transplant. Proc. pmid:9365627
Hryniewiecka E et al. Arterial hypertension in liver transplant recipients. 2011 Transplant. Proc. pmid:21996217
Mayer AD Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study. 2002 Transplant. Proc. pmid:12176452
Bäckman L et al. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. 1994 Transplant. Proc. pmid:7518160
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Celli S et al. Mechanisms of protection from humoral rejection by a xenografted liver. 1995 Transplant. Proc. pmid:7533395
Woodle ES et al. FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. 1991 Transplant. Proc. pmid:1721337
Weimer R et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. 2005 Transplant. Proc. pmid:15919463
Allers C et al. Tacrolimus, daclizumab, sirolimus, and budesonide after small bowel transplantation in order to reduce nephrotoxicity. 2002 Transplant. Proc. pmid:12034251
Rosh JR et al. Therapy with FK 506 in pediatric liver recipients. 1994 Transplant. Proc. pmid:7509091
Scantlebury VP et al. Pediatric kidney transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7509095
Souza ER et al. Acute effects of FK 506 on glomerular hemodynamics. 1992 Transplant. Proc. pmid:1281585
Takayama J et al. Living related liver transplantation in patients with ABO incompatibility. 1998 Transplant. Proc. pmid:9838537
Hamano I et al. Condyloma Acuminata of the Urethra in a Male Renal Transplant Recipient: A Case Report. 2018 Transplant. Proc. pmid:30316397
Darras FS et al. Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721368
Wu MS et al. Cyclosporine, but not FK 506 and rapamycin, enhances cell proliferation in mouse medullary thick ascending cultured cells. 1998 Transplant. Proc. pmid:9838561
Shapiro R et al. Kidney transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703352
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Scott JS et al. Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? 1999 Feb-Mar Transplant. Proc. pmid:10083017
Tzakis AG et al. Use of FK 506 in pediatric patients. 1991 Transplant. Proc. pmid:1703353
Meiser BM et al. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. 1999 Feb-Mar Transplant. Proc. pmid:10083018
Crespo-Leiro MG Tacrolimus in heart transplantation. 2003 Transplant. Proc. pmid:12962869
Rayes N et al. Distribution of lymphocyte subtypes in liver transplant recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123103
Platz KP et al. Impact of immunosuppression and acute rejection on hepatitis B recurrence. 1997 Feb-Mar Transplant. Proc. pmid:9123107
Asfar S et al. Small bowel transplantation. 1996 Transplant. Proc. pmid:8908039
Reyes J et al. Intestinal transplantation in children: five-year experience. 1996 Transplant. Proc. pmid:8908042
Dietl KH Oral dosing of tacrolimus and cyclosporine microemulsion--results from a large multicenter study in renal transplantation. 2002 Transplant. Proc. pmid:12176524
San Miguel C et al. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. 2015 Transplant. Proc. pmid:26518930
Miura K et al. Development of the Intestinal Transplantation Model With Major Histocompatibility Complex Inbred CLAWN Miniature Swine. 2016 Transplant. Proc. pmid:27320612
Lee HK et al. Expression of Endoplasmic Reticulum-Mediated Stress Proteins in FK506-Treated T-Lymphocytes. 2016 Transplant. Proc. pmid:27320607
Ito A et al. Induction of tolerance in rat cardiac allograft model by intrathymic injection of donor bone marrow cells. 1995 Transplant. Proc. pmid:7536974
Park JW et al. Invasive pulmonary aspergillosis after living donor liver transplantation should be eradicated or not? A case report. 2011 Jul-Aug Transplant. Proc. pmid:21839284
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Steinmueller T et al. The effect of cyclosporine vs FK 506 on glucose metabolism. 1999 Feb-Mar Transplant. Proc. pmid:10083504
Moutabarrik A et al. Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. 1993 Transplant. Proc. pmid:7685949
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Bhaloo S and Prasad GV Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. 2003 Transplant. Proc. pmid:14611983
Iacona I et al. Mycophenolic acid in combination with FK 506: a pharmacokinetic study in piglets after small-bowel transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123489
Migita K and Eguchi K FK 506-mediated T-cell apoptosis induction. 2001 Transplant. Proc. pmid:11377532
Omoto K et al. Adverse events in renal transplantation under tacrolimus/mycophnolate mofetil immunosuppression: a single-center experience. 2002 Transplant. Proc. pmid:12176591
Nakache R et al. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization. 2001 Transplant. Proc. pmid:11377533
Baran DA et al. A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results. 2002 Transplant. Proc. pmid:12176595
Canivet C et al. T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus. 2008 Transplant. Proc. pmid:19100403
Maass E et al. Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. 2007 Transplant. Proc. pmid:18089410
Shishido S et al. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267193
Valdivia LA et al. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721432
Kawano K et al. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. 1996 Transplant. Proc. pmid:8658938
Ochiai T et al. Prolongation of canine renal allograft survival by treatment with FK-506. 1987 Transplant. Proc. pmid:2445075
Atillasoy E et al. Cholesterol levels long-term after liver transplant. 1998 Transplant. Proc. pmid:9723387
Quijano Y et al. Tolerance: a study in long-term surviving animals after small bowel transplantation. 1998 Transplant. Proc. pmid:9745494
Ito T et al. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report. Transplant. Proc. pmid:26915883
Lee KM and Eun SC Experimental canine facial transplantation. 2014 Transplant. Proc. pmid:24815162
Banerjee R et al. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267435
Shingaki S et al. Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. Transplant. Proc. pmid:29407317
Mehra MR et al. A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267438
McManus BM et al. Impact of FK 506 on myocarditis in the enteroviral murine model. 1991 Transplant. Proc. pmid:1721463
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Fujimura T et al. Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636413
Yoshimura N et al. Development of a macromolecular prodrug of FK 506: III: In vivo disposition of FK 506-dextran conjugate. 1998 Transplant. Proc. pmid:9636415
Tariciotti L et al. Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. 2016 Transplant. Proc. pmid:27932158
Sevmis S et al. Tacrolimus-related seizure in the early postoperative period after liver transplantation. 2007 Transplant. Proc. pmid:17524935
Ott R et al. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750359
Badiou S et al. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? 2006 Transplant. Proc. pmid:16980076
Goto S et al. Effect of FK 506 and cyclosporine on heart allograft survival in rats. 1991 Transplant. Proc. pmid:1703700
White SA et al. Influence of delayed graft function in renal transplants from cadaveric or non-heart-beating donors. 2000 Transplant. Proc. pmid:10701018
Sens YA et al. Posttransplant diabetes mellitus in renal transplant patients with hepatitis C virus. 2004 Transplant. Proc. pmid:15194304
Kliem V et al. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. 1998 Transplant. Proc. pmid:9636509